Reflections of Oxygen Delivery Methods Applied in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) on Blood Gas and Spirometer Measurements
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Arterial blood gas and spirometry values will be examined before and after treatment administration to patients.
研究概览
简要总结
To examine the effects of oxygen therapy methods applied as indicated in COPD acute exacerbations on blood gas results and spirometric measurements.
详细描述
Patients requiring non-invasive ventilation will be divided into two groups: one group will receive NIMV in the form of Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP). The other group will receive EzPAP® (a non-invasive positive airway pressure device). For both groups, blood gas results and hand-held spirometer parameters, including Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF), and Forced Expiratory Volume in one second (FEV1), will be evaluated before and after the application.It is aimed to evaluate the effect of COPD noninvasive treatment methods on hospitalization and mortality processes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with acute exacerbation of COPD,
- •Those without a history of trauma,
- •Patients who have not undergone any lung surgery previously,
- •Patients capable of providing written and verbal consent.
排除标准
- •Patients without acute exacerbation of COPD,
- •Pregnancy, suspected pregnancy,
- •Those who have undergone any lung surgery previously,
- •Patients with a history of trauma,
- •Intubated patients and those not compliant with treatments,
- •Patients unable to provide written and verbal consent.
结局指标
主要结局
Arterial blood gas and spirometry values will be examined before and after treatment administration to patients.
时间窗: Patients will receive 2-hour treatment (EzPAP and NIMV) and then measurements will be taken 30 minutes after the completion of treatment in both groups.
Patients meeting the inclusion criteria will be enrolled in the study after obtaining informed consent. 1. Before treatment, the following parameters will be assessed: * Blood pressure (mmHg) * Oxygen Saturation (%) * Respiratory rate /min, * Heart rate/min * pH * pCO2-mmHg * PaO2-mmHg * HCO3-mEq/L * Lactate-mmol/L * FEV1-Liter * FVC-Liter * \- PEF-L/min 2. After treatment, the following parameters will be assessed: * Blood pressure (mmHg) * Oxygen Saturation (%) * Respiratory rate /min, * Heart rate/min * pH * pCO2-mmHg * PaO2-mmHg * HCO3-mEq/L * Lactate-mmol/L * FEV1-Liter * FVC-Liter * PEF-L/min
Evaluation of the patient's mortalite after treatment.
时间窗: The 30-day mortality of the patients will be evaluated.
\- 30-day mortality of the patients will be evaluated.
次要结局
未报告次要终点
研究者
Emine Sarcan
Doctor
Ankara Etlik City Hospital